Federal Contractor Profile
Emergent Product Development Gaithersburg INC.
$2.5B obligated·16 awards·2 agencies·6 NAICS
Federal Contracts
Showing award actions 51–62 of 62 funded award actions, most recent first.
- Contracts with positive obligations
- 16
- Funded award actions shown
- 62
- Obligations shown
- $2.5B
- Awarding agencies
- 2
This table shows award actions with a positive obligation. Zero-dollar and negative-dollar actions, such as administrative changes and deobligations, are not displayed. Multiple award actions may belong to the same contract.
Award data as of August 18, 2026. Source: USAspending federal award records.
| Date | Agency | PIID | NAICS | Description | Amount |
|---|---|---|---|---|---|
| Nov 21, 2017 | Department of DefenseDEFENSE THREAT REDUCTION AGENCY | HDTRA114C0122 | 541711 | IGF::OT::IGF, THE FIRST ORAL ANTIBIOTIC FOR THE TREATMENT OF ACUTE MELIODOSIS AND SELECT AGENTS" FOR MODIFICATIONS P00011, 12 AND 13. | $100K |
| Nov 16, 2017 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | HHSO100201500004C | 541711 | IGF::OT::IGF FOR OTHER FUNCTIONSTHIS CONTRACT IS FOR THE ADVANCED DEVELOPMENT OF NUTHRAX (ANTHRAX VACCINE ABSORBED WITH CPG 7909) OR AV7909 | $4.8M |
| Sep 15, 2017 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | HHSO100201700001C | 541711 | IGF::OT::IGF - ADVANCING STABILIZED ISOAMYL NITRITE FOR INTRANASAL TREATMENT OF CYANIDE EXPOSURE | $13M |
| Sep 13, 2017 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | HHSN272201400038C | 541712 | IGF::OT::IGF DEVELOPMENT OF VACCINE FORMULATIONS EFFECTIVE AGAINST NIAID PRIORITY PATHOGENS | $1.5M |
| Aug 11, 2017 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | HHSN272201400038C | 541712 | IGF::OT::IGF DEVELOPMENT OF VACCINE FORMULATIONS EFFECTIVE AGAINST NIAID PRIORITY PATHOGENS | $1.9M |
| Jun 30, 2017 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | HHSN272201400038C | 541712 | IGF::OT::IGF DEVELOPMENT OF VACCINE FORMULATIONS EFFECTIVE AGAINST NIAID PRIORITY PATHOGENS | $1.8M |
| Mar 23, 2017 | Department of DefenseDEFENSE THREAT REDUCTION AGENCY | HDTRA114C0122 | 541711 | IGF::OT::IGF, THE FIRST ORAL ANTIBIOTIC FOR THE TREATMENT OF ACUTE MELIODOSIS AND SELECT AGENTS" FOR MODIFICATIONS P00011, 12 AND 13. | $697K |
| Mar 10, 2017 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | HHSN272201400038C | 541712 | IGF::OT::IGF DEVELOPMENT OF VACCINE FORMULATIONS EFFECTIVE AGAINST NIAID PRIORITY PATHOGENS | $3.5M |
| Oct 31, 2016 | Department of DefenseDEFENSE THREAT REDUCTION AGENCY | HDTRA114C0122 | 541711 | IGF::OT::IGF, THE FIRST ORAL ANTIBIOTIC FOR THE TREATMENT OF ACUTE MELIODOSIS AND SELECT AGENTS" FOR MODIFICATIONS P00011, 12 AND 13. | $803K |
| Sep 30, 2016 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | HHSO100201600030C | 541711 | IGF::OT::IGF | $199M |
| Mar 16, 2016 | Department of Health and Human ServicesNIH, NIAID DEA OA OFC ACQUISITIONS | HHSN272201400038C | 541712 | IGF::OT::IGF DEVELOPMENT OF VACCINE FORMULATIONS EFFECTIVE AGAINST NIAID PRIORITY PATHOGENS | $4.2M |
| Oct 30, 2015 | Department of Health and Human ServicesOFF ASST SEC ADM AND MGMT | HHSO100201500004C | 541711 | IGF::OT::IGF FOR OTHER FUNCTIONSTHIS CONTRACT IS FOR THE ADVANCED DEVELOPMENT OF NUTHRAX (ANTHRAX VACCINE ABSORBED WITH CPG 7909) OR AV7909 | $4.0M |
Get Alerted Before Emergent Product Development Gaithersburg INC.'s Next Recompete
Mindy monitors active contracts and flags recompetes 12 months out so you can position to compete.
Start Free